NEW YORK, September 22, 2016 /PRNewswire/ --
Today, Stock-Callers.com has initiated research reports on these biotech stocks: Portola Pharmaceuticals Inc. (NASDAQ: PTLA), bluebird bio Inc. (NASDAQ: BLUE), Auris Medical Holding A.G. (NASDAQ: EARS), and Cerulean Pharma Inc. (NASDAQ: CERU). Yesterday, the markets were on a bullish course with all indices in the green. The NASDAQ Composite ended the trading session at up 1.03%; the Dow Jones Industrial Average edged 0.90% higher; and the S&P 500 closed up 1.09%. The gains were broad based as all the sectors ended the session in positive. Learn more about these stocks by accessing their free research reports at:
South San Francisco, California headquartered Portola Pharmaceuticals Inc.'s stock advanced 1.36%, to close the day at $23.80. The stock recorded a trading volume of 717,613 shares. Shares of Portola Pharmaceuticals, which develops and commercializes therapeutics for patients in the areas of thrombosis, other hematologic disorders, and inflammation, have gained 23.83% in the last one month. The company's shares are trading 1.45% above its 50-day moving average. Additionally, the stock has a Relative Strength Index (RSI) of 58.23. Free research report on PTLA is available at:
Cambridge, Massachusetts headquartered bluebird bio Inc.'s stock finished Wednesday's session 0.05% higher at $73.81 with a total volume of 1.51 million shares traded. Over the last one month and the previous three months, shares of bluebird bio, which focuses on developing transformative gene therapies for severe genetic and rare diseases, have surged 34.91% and 83.52%, respectively. The Company's shares are trading above its 50-day and 200-day moving averages by 35.27% and 49.19%, respectively. bluebird bio's stock has an RSI of 74.87. The complimentary research report on BLUE can be downloaded at:
Auris Medical Holding
On Wednesday, shares in Zug, Switzerland-based Auris Medical Holding A.G. ended the session 1.21% lower at $1.63 with a total volume of 231,672 shares traded. The stock is trading 46.35% below its 50-day moving average. Moreover, shares of the Company, which focuses on the development of novel products for the treatment of inner ear disorders, have an RSI of 35.15. Visit us today and access our complete research report on EARS at:
On Wednesday, shares in Waltham, Massachusetts-based Cerulean Pharma Inc. recorded a trading volume of 107,319 shares. The stock ended the day 0.01% lower at $0.95. The company is trading below its 50-day moving average by 51.63%. Furthermore, shares of Cerulean Pharma, which develops nanotechnology-based therapeutics in the areas of oncology and other diseases in the US, have an RSI of 20.22.
On August 30th, 2016, research firm Barclays reiterated its 'Overweight' rating on the Company's stock with a decrease of the target price from $5 a share to $2 a share. Get free access to your research report on CERU at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: firstname.lastname@example.org Phone number: +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA